Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Kabra Drugs has informed that a meeting of the Board of Directors of is scheduled to be held on Thursday 1 January 2026, at the Corporate office at Chennai of the Company, inter alia, to consider and approve the following strategic business items: 1. Change of Name of the Company 2. Strategic Acquisitions 3. Alteration of the Main Objects (MOA) 4. Any other agenda with the permission of the chair.
The above information is a part of company’s filings submitted to BSE.
